1-7 of 7
Rosemarie Mick
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PR05: Peripheral blood immune profiling of anti-PD-1 therapy in human melanoma reveals a link between T cell re-invigoration and tumor burden that predicts response

Free
Alexander Huang, Michael A. Postow, Robert J. Orlowski, Rosemarie Mick, Bertram Bengsch, Sasi Manne, Wei Xu, Shannon Harmon, Matthew Adamow, Deborah Kuk, Katherine Panangeas, Cristina Carerra, Phillip Wong, Felix Quagliarello, Kristen E. Pauken, Ramin S. Herati, Suzanne McGettigan, Shawn Kothari, Sangeeth M. George, Brandon Wenz, Kurt D'Andrea, Xiaowei Xu, Ravi K. Amaravadi, Giorgos Karakousis, Lynn M. Schuchter, Katherine L. Nathanson, Jedd D. Wolchok, Tara C. Gangadhar, John Wherry
Journal: Cancer Immunology Research
Cancer Immunol Res (2016) 4 (11_Supplement): PR05.
https://doi.org/10.1158/2326-6066.IMM2016-PR05
Published: 31 October 2016
View articletitled, Abstract PR05: Peripheral blood immune profiling of anti-PD-1 therapy in human melanoma reveals a link between T cell re-invigoration and tumor burden that predicts response
Journal Articles

Abstract A056: Mechanisms of tumor response and resistance to radiation and dual checkpoint blockade in mice and patients

Free
Christina Twyman-Saint Victor, Andrew Rech, Amit Maity, Ramesh Rengan, Kristen Pauken, Erietta Stelekati, Joseph Benci, Bihui Xu, Hannah Dada, Pamela Odorizzi, Ramin Herati, Kathleen Mansfield, Dana Patsch, Ravi Amaravadi, Lynn Schuchter, Hemant Ishwaran, Rosemarie Mick, Daniel Pryma, Xiaowei Xu, Michael Feldman, Tara Gangadhar, Stephen Hahn, E. John Wherry, Robert Vonderheide, Andy Minn
Journal: Cancer Immunology Research
Cancer Immunol Res (2016) 4 (1_Supplement): A056.
https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR15-A056
Published: 03 January 2016
View articletitled, Abstract A056: Mechanisms of tumor response and resistance to radiation and dual checkpoint blockade in mice and patients
Journal Articles

Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies

Free
Rosemarie Mick, Tai-Tsang Chen
Journal: Cancer Immunology Research
Cancer Immunol Res (2015) 3 (12): 1292–1298.
https://doi.org/10.1158/2326-6066.CIR-15-0260
Published: 06 December 2015
View articletitled, Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies
Open the PDF for Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies in another window
Journal Articles

Abstract A10: Soluble CD25 and C-reactive protein predict overall survival in melanoma patients receiving anti-CD40 monoclonal antibody CP-870,893 (αCD40) and anti-CTLA4 monoclonal antibody tremelimumab

Free
Rosemarie Mick, David Bajor, Lee Richman, Robert Vonderheide
Journal: Cancer Immunology Research
Cancer Immunol Res (2015) 3 (10_Supplement): A10.
https://doi.org/10.1158/2326-6074.TUMIMM14-A10
Published: 09 October 2015
View articletitled, Abstract A10: Soluble CD25 and C-reactive protein predict overall survival in melanoma patients receiving anti-CD40 monoclonal antibody CP-870,893 (αCD40) and anti-CTLA4 monoclonal antibody tremelimumab
Journal Articles

Abstract A38: Phase I study of combination immunotherapy with agonistic CD40 monoclonal antibody (mAb) CP-870,893 (αCD40) and anti-CTLA-4 antibody tremelimumab (treme) in patients with metastatic melanoma

Free
David L. Bajor, Rosemarie Mick, Matthew J. Riese, Richman P. Lee, Xiaowei Xu, Drew A. Torigian, Erietta Stelekati, Martha Sweeney, Brendan J. Sullivan, Lynn M. Schuchter, Ravi Amaravadi, E John Wherry, Robert H. Vonderheide
Journal: Cancer Immunology Research
Cancer Immunol Res (2015) 3 (10_Supplement): A38.
https://doi.org/10.1158/2326-6074.TUMIMM14-A38
Published: 09 October 2015
View articletitled, Abstract A38: Phase I study of combination immunotherapy with agonistic CD40 monoclonal antibody (mAb) CP-870,893 (αCD40) and anti-CTLA-4 antibody tremelimumab (treme) in patients with metastatic melanoma
Journal Articles

Abstract A52: Radiation and dual PD-L1 and CTLA4 checkpoint blockade non-redundantly improves tumor resistance, response, and immunity

Free
Andrew J. Rech, Christina Twyman, Amit Maity, Ramesh Rengan, Kristen E. Pauken, Erietta Stelekati, Bihui Xu, Hannah Dada, Pamela M. Odorizzi, Ramin D. Herati, Kathleen D. Mansfield, Dana Patsch, Ravi Amaravadi, Lynn Schuchter, Hemant Ishwaran, Rosemarie Mick, Daniel Pryma, George Xu, Michael Feldman, Tara C. Gangadhar, Stephen Hahn, E. John Wherry, Andy J. Minn, Robert H. Vonderheide
Journal: Cancer Immunology Research
Cancer Immunol Res (2015) 3 (10_Supplement): A52.
https://doi.org/10.1158/2326-6074.TUMIMM14-A52
Published: 09 October 2015
View articletitled, Abstract A52: Radiation and dual PD-L1 and CTLA4 checkpoint blockade non-redundantly improves tumor resistance, response, and immunity
Journal Articles

Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma

Free
David L. Bajor, Xiaowei Xu, Drew A. Torigian, Rosemarie Mick, Laura R. Garcia, Lee P. Richman, Cindy Desmarais, Katherine L. Nathanson, Lynn M. Schuchter, Michael Kalos, Robert H. Vonderheide
Journal: Cancer Immunology Research
Cancer Immunol Res (2014) 2 (11): 1051–1058.
https://doi.org/10.1158/2326-6066.CIR-14-0154
Published: 02 November 2014
View articletitled, Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma
Open the PDF for Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma in another window